nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—muscle cancer	0.724	1	CbGaD
Clodronate—SLC25A6—Mitochondrial protein import—TIMM10—muscle cancer	0.023	0.223	CbGpPWpGaD
Clodronate—SLC25A4—Mitochondrial protein import—TIMM10—muscle cancer	0.0179	0.174	CbGpPWpGaD
Clodronate—SLC25A5—Interactions of Vpr with host cellular proteins—HMGA1—muscle cancer	0.00881	0.0855	CbGpPWpGaD
Clodronate—SLC25A6—embryo—muscle cancer	0.00795	0.0755	CbGeAlD
Clodronate—SLC25A6—Interactions of Vpr with host cellular proteins—HMGA1—muscle cancer	0.00738	0.0716	CbGpPWpGaD
Clodronate—SLC25A6—Vinorelbine—Vincristine—muscle cancer	0.00718	1	CbGdCrCtD
Clodronate—SLC25A5—embryo—muscle cancer	0.00691	0.0657	CbGeAlD
Clodronate—SLC25A6—renal system—muscle cancer	0.00602	0.0572	CbGeAlD
Clodronate—SLC25A4—Interactions of Vpr with host cellular proteins—HMGA1—muscle cancer	0.00576	0.0559	CbGpPWpGaD
Clodronate—SLC25A5—smooth muscle tissue—muscle cancer	0.00544	0.0517	CbGeAlD
Clodronate—SLC25A5—renal system—muscle cancer	0.00523	0.0497	CbGeAlD
Clodronate—SLC25A4—renal system—muscle cancer	0.0049	0.0466	CbGeAlD
Clodronate—SLC25A5—cardiac atrium—muscle cancer	0.00469	0.0445	CbGeAlD
Clodronate—PTGS2—hindlimb—muscle cancer	0.00457	0.0434	CbGeAlD
Clodronate—SLC25A6—bone marrow—muscle cancer	0.00455	0.0432	CbGeAlD
Clodronate—Myeloid leukaemia—Doxorubicin—muscle cancer	0.00451	0.0741	CcSEcCtD
Clodronate—SLC25A4—cardiac atrium—muscle cancer	0.00439	0.0417	CbGeAlD
Clodronate—SLC25A5—tendon—muscle cancer	0.00408	0.0388	CbGeAlD
Clodronate—SLC25A6—head—muscle cancer	0.00402	0.0382	CbGeAlD
Clodronate—SLC25A5—bone marrow—muscle cancer	0.00396	0.0376	CbGeAlD
Clodronate—PTGS2—appendage—muscle cancer	0.00392	0.0373	CbGeAlD
Clodronate—SLC25A6—testis—muscle cancer	0.00389	0.0369	CbGeAlD
Clodronate—SLC25A4—tendon—muscle cancer	0.00383	0.0364	CbGeAlD
Clodronate—SLC25A5—vagina—muscle cancer	0.00379	0.036	CbGeAlD
Clodronate—SLC25A4—vagina—muscle cancer	0.00355	0.0338	CbGeAlD
Clodronate—SLC25A5—head—muscle cancer	0.0035	0.0333	CbGeAlD
Clodronate—SLC25A5—testis—muscle cancer	0.00338	0.0321	CbGeAlD
Clodronate—SLC25A4—head—muscle cancer	0.00328	0.0312	CbGeAlD
Clodronate—Acute leukaemia—Etoposide—muscle cancer	0.00319	0.0524	CcSEcCtD
Clodronate—SLC25A4—testis—muscle cancer	0.00317	0.0301	CbGeAlD
Clodronate—SLC25A5—Host Interactions of HIV factors—HMGA1—muscle cancer	0.00309	0.03	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—TIMM10—muscle cancer	0.00293	0.0284	CbGpPWpGaD
Clodronate—Acute myeloid leukaemia—Doxorubicin—muscle cancer	0.00288	0.0473	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—TP73—muscle cancer	0.00276	0.0268	CbGpPWpGaD
Clodronate—SLC25A6—Host Interactions of HIV factors—HMGA1—muscle cancer	0.00259	0.0251	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—TIMM10—muscle cancer	0.00229	0.0222	CbGpPWpGaD
Clodronate—SLC25A4—Host Interactions of HIV factors—HMGA1—muscle cancer	0.00202	0.0196	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—HMGA1—muscle cancer	0.00201	0.0195	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—MYF6—muscle cancer	0.00183	0.0178	CbGpPWpGaD
Clodronate—SLC25A6—HIV Infection—HMGA1—muscle cancer	0.00168	0.0163	CbGpPWpGaD
Clodronate—Acute leukaemia—Doxorubicin—muscle cancer	0.00166	0.0272	CcSEcCtD
Clodronate—Extravasation—Dactinomycin—muscle cancer	0.00144	0.0237	CcSEcCtD
Clodronate—Hyperphosphataemia—Doxorubicin—muscle cancer	0.00139	0.0227	CcSEcCtD
Clodronate—Hypocalcaemia—Dactinomycin—muscle cancer	0.00138	0.0226	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—HMGA1—muscle cancer	0.00131	0.0127	CbGpPWpGaD
Clodronate—PTGS2—embryo—muscle cancer	0.0013	0.0124	CbGeAlD
Clodronate—Extravasation—Vincristine—muscle cancer	0.00129	0.0212	CcSEcCtD
Clodronate—Extravasation—Etoposide—muscle cancer	0.00105	0.0172	CcSEcCtD
Clodronate—PTGS2—smooth muscle tissue—muscle cancer	0.00102	0.00973	CbGeAlD
Clodronate—PTGS2—renal system—muscle cancer	0.000985	0.00936	CbGeAlD
Clodronate—SLC25A5—Metabolism—FH—muscle cancer	0.00088	0.00853	CbGpPWpGaD
Clodronate—Local reaction—Doxorubicin—muscle cancer	0.000855	0.014	CcSEcCtD
Clodronate—Liver disorder—Methotrexate—muscle cancer	0.000802	0.0132	CcSEcCtD
Clodronate—Dysphagia—Dactinomycin—muscle cancer	0.000791	0.013	CcSEcCtD
Clodronate—Serum creatinine increased—Doxorubicin—muscle cancer	0.000769	0.0126	CcSEcCtD
Clodronate—PTGS2—tendon—muscle cancer	0.000769	0.00731	CbGeAlD
Clodronate—Dehydration—Vincristine—muscle cancer	0.00076	0.0125	CcSEcCtD
Clodronate—PTGS2—bone marrow—muscle cancer	0.000745	0.00708	CbGeAlD
Clodronate—SLC25A6—Metabolism—FH—muscle cancer	0.000737	0.00715	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CD34—muscle cancer	0.000729	0.00707	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—MYOD1—muscle cancer	0.000729	0.00707	CbGpPWpGaD
Clodronate—PTGS2—vagina—muscle cancer	0.000714	0.00678	CbGeAlD
Clodronate—Pneumonia—Dactinomycin—muscle cancer	0.000709	0.0116	CcSEcCtD
Clodronate—Hypercalcaemia—Doxorubicin—muscle cancer	0.000681	0.0112	CcSEcCtD
Clodronate—Cardiac failure—Etoposide—muscle cancer	0.000679	0.0111	CcSEcCtD
Clodronate—PTGS2—head—muscle cancer	0.000659	0.00627	CbGeAlD
Clodronate—Pneumonia—Vincristine—muscle cancer	0.000634	0.0104	CcSEcCtD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—muscle cancer	0.000629	0.0061	CbGpPWpGaD
Clodronate—Pharyngitis—Dactinomycin—muscle cancer	0.000628	0.0103	CcSEcCtD
Clodronate—Extravasation—Methotrexate—muscle cancer	0.000626	0.0103	CcSEcCtD
Clodronate—Proteinuria—Methotrexate—muscle cancer	0.000622	0.0102	CcSEcCtD
Clodronate—Protein urine present—Methotrexate—muscle cancer	0.000613	0.0101	CcSEcCtD
Clodronate—Oliguria—Methotrexate—muscle cancer	0.000593	0.00974	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Etoposide—muscle cancer	0.000584	0.00959	CcSEcCtD
Clodronate—SLC25A4—Metabolism—FH—muscle cancer	0.000575	0.00558	CbGpPWpGaD
Clodronate—Dysphagia—Etoposide—muscle cancer	0.000572	0.0094	CcSEcCtD
Clodronate—Bronchospasm—Etoposide—muscle cancer	0.000563	0.00925	CcSEcCtD
Clodronate—Urinary tract disorder—Vincristine—muscle cancer	0.000559	0.00917	CcSEcCtD
Clodronate—Connective tissue disorder—Vincristine—muscle cancer	0.000556	0.00913	CcSEcCtD
Clodronate—Urethral disorder—Vincristine—muscle cancer	0.000554	0.00911	CcSEcCtD
Clodronate—Neoplasm malignant—Doxorubicin—muscle cancer	0.000554	0.0091	CcSEcCtD
Clodronate—PTGS2—S1P1 pathway—VEGFA—muscle cancer	0.000548	0.00532	CbGpPWpGaD
Clodronate—Extravasation—Doxorubicin—muscle cancer	0.000542	0.00891	CcSEcCtD
Clodronate—SLC25A5—Disease—ENO2—muscle cancer	0.000541	0.00525	CbGpPWpGaD
Clodronate—Hypocalcaemia—Doxorubicin—muscle cancer	0.000517	0.00849	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000514	0.00499	CbGpPWpGaD
Clodronate—Oliguria—Doxorubicin—muscle cancer	0.000513	0.00843	CcSEcCtD
Clodronate—Pneumonia—Etoposide—muscle cancer	0.000513	0.00843	CcSEcCtD
Clodronate—Mediastinal disorder—Vincristine—muscle cancer	0.00051	0.00837	CcSEcCtD
Clodronate—Anaemia—Dactinomycin—muscle cancer	0.000509	0.00836	CcSEcCtD
Clodronate—Renal failure—Etoposide—muscle cancer	0.000502	0.00824	CcSEcCtD
Clodronate—Creatinine increased—Doxorubicin—muscle cancer	0.000497	0.00816	CcSEcCtD
Clodronate—SLC25A5—Metabolism—MED12—muscle cancer	0.000497	0.00482	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HMGA1—muscle cancer	0.000492	0.00477	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—IGF2—muscle cancer	0.000482	0.00468	CbGpPWpGaD
Clodronate—Hepatocellular injury—Doxorubicin—muscle cancer	0.000473	0.00777	CcSEcCtD
Clodronate—Anaemia—Vincristine—muscle cancer	0.000455	0.00747	CcSEcCtD
Clodronate—SLC25A6—Disease—ENO2—muscle cancer	0.000453	0.0044	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—ENO2—muscle cancer	0.000453	0.0044	CbGpPWpGaD
Clodronate—Urinary tract disorder—Etoposide—muscle cancer	0.000452	0.00743	CcSEcCtD
Clodronate—Urethral disorder—Etoposide—muscle cancer	0.000449	0.00738	CcSEcCtD
Clodronate—Infection—Dactinomycin—muscle cancer	0.000447	0.00734	CcSEcCtD
Clodronate—SLC25A5—Disease—FOXO4—muscle cancer	0.000441	0.00428	CbGpPWpGaD
Clodronate—Renal failure acute—Methotrexate—muscle cancer	0.00043	0.00706	CcSEcCtD
Clodronate—Anorexia—Dactinomycin—muscle cancer	0.000429	0.00704	CcSEcCtD
Clodronate—SLC25A6—Metabolism—MED12—muscle cancer	0.000416	0.00404	CbGpPWpGaD
Clodronate—Mediastinal disorder—Etoposide—muscle cancer	0.000413	0.00678	CcSEcCtD
Clodronate—SLC25A6—Disease—HMGA1—muscle cancer	0.000412	0.004	CbGpPWpGaD
Clodronate—Infection—Vincristine—muscle cancer	0.000399	0.00656	CcSEcCtD
Clodronate—Hepatic function abnormal—Doxorubicin—muscle cancer	0.000393	0.00646	CcSEcCtD
Clodronate—Decreased appetite—Dactinomycin—muscle cancer	0.000391	0.00642	CcSEcCtD
Clodronate—Anorexia—Vincristine—muscle cancer	0.000383	0.00629	CcSEcCtD
Clodronate—SLC25A6—Metabolism—ENO2—muscle cancer	0.00038	0.00368	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—IGF2—muscle cancer	0.000376	0.00365	CbGpPWpGaD
Clodronate—Renal failure acute—Doxorubicin—muscle cancer	0.000372	0.00611	CcSEcCtD
Clodronate—SLC25A6—Disease—FOXO4—muscle cancer	0.00037	0.00359	CbGpPWpGaD
Clodronate—Anaemia—Etoposide—muscle cancer	0.000369	0.00605	CcSEcCtD
Clodronate—Renal impairment—Doxorubicin—muscle cancer	0.000361	0.00593	CcSEcCtD
Clodronate—Abdominal pain—Dactinomycin—muscle cancer	0.000356	0.00584	CcSEcCtD
Clodronate—SLC25A4—Disease—ENO2—muscle cancer	0.000354	0.00343	CbGpPWpGaD
Clodronate—Cardiac failure—Doxorubicin—muscle cancer	0.000352	0.00578	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000351	0.00341	CbGpPWpGaD
Clodronate—Decreased appetite—Vincristine—muscle cancer	0.000349	0.00574	CcSEcCtD
Clodronate—Gastrointestinal disorder—Vincristine—muscle cancer	0.000347	0.0057	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000337	0.00554	CcSEcCtD
Clodronate—SLC25A5—Disease—FOXO1—muscle cancer	0.000326	0.00316	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—MED12—muscle cancer	0.000325	0.00315	CbGpPWpGaD
Clodronate—Infection—Etoposide—muscle cancer	0.000323	0.00531	CcSEcCtD
Clodronate—Blood creatinine increased—Doxorubicin—muscle cancer	0.000322	0.00529	CcSEcCtD
Clodronate—SLC25A4—Disease—HMGA1—muscle cancer	0.000322	0.00312	CbGpPWpGaD
Clodronate—Dehydration—Doxorubicin—muscle cancer	0.000319	0.00525	CcSEcCtD
Clodronate—Abdominal pain—Vincristine—muscle cancer	0.000318	0.00522	CcSEcCtD
Clodronate—Skin disorder—Etoposide—muscle cancer	0.000316	0.00519	CcSEcCtD
Clodronate—Abdominal pain upper—Doxorubicin—muscle cancer	0.000314	0.00515	CcSEcCtD
Clodronate—Anorexia—Etoposide—muscle cancer	0.00031	0.0051	CcSEcCtD
Clodronate—Diarrhoea—Dactinomycin—muscle cancer	0.000308	0.00505	CcSEcCtD
Clodronate—Pneumonia—Methotrexate—muscle cancer	0.000307	0.00505	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000303	0.00498	CcSEcCtD
Clodronate—Renal failure—Methotrexate—muscle cancer	0.000301	0.00494	CcSEcCtD
Clodronate—Dysphagia—Doxorubicin—muscle cancer	0.000297	0.00488	CcSEcCtD
Clodronate—SLC25A4—Metabolism—ENO2—muscle cancer	0.000296	0.00288	CbGpPWpGaD
Clodronate—Dyspnoea—Etoposide—muscle cancer	0.00029	0.00477	CcSEcCtD
Clodronate—SLC25A4—Disease—FOXO4—muscle cancer	0.000289	0.0028	CbGpPWpGaD
Clodronate—Vomiting—Dactinomycin—muscle cancer	0.000286	0.0047	CcSEcCtD
Clodronate—Rash—Dactinomycin—muscle cancer	0.000284	0.00466	CcSEcCtD
Clodronate—Decreased appetite—Etoposide—muscle cancer	0.000283	0.00465	CcSEcCtD
Clodronate—Gastrointestinal disorder—Etoposide—muscle cancer	0.000281	0.00462	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—KIT—muscle cancer	0.000279	0.00271	CbGpPWpGaD
Clodronate—Diarrhoea—Vincristine—muscle cancer	0.000275	0.00452	CcSEcCtD
Clodronate—SLC25A6—Disease—FOXO1—muscle cancer	0.000273	0.00265	CbGpPWpGaD
Clodronate—Pharyngitis—Methotrexate—muscle cancer	0.000272	0.00447	CcSEcCtD
Clodronate—Urinary tract disorder—Methotrexate—muscle cancer	0.000271	0.00445	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.00027	0.00262	CbGpPWpGaD
Clodronate—Urethral disorder—Methotrexate—muscle cancer	0.000269	0.00442	CcSEcCtD
Clodronate—Nausea—Dactinomycin—muscle cancer	0.000267	0.00439	CcSEcCtD
Clodronate—Pneumonia—Doxorubicin—muscle cancer	0.000266	0.00437	CcSEcCtD
Clodronate—Renal failure—Doxorubicin—muscle cancer	0.00026	0.00427	CcSEcCtD
Clodronate—Urticaria—Etoposide—muscle cancer	0.000259	0.00425	CcSEcCtD
Clodronate—Abdominal pain—Etoposide—muscle cancer	0.000257	0.00423	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000257	0.00249	CbGpPWpGaD
Clodronate—Vomiting—Vincristine—muscle cancer	0.000255	0.0042	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000254	0.00246	CbGpPWpGaD
Clodronate—Rash—Vincristine—muscle cancer	0.000253	0.00416	CcSEcCtD
Clodronate—Dermatitis—Vincristine—muscle cancer	0.000253	0.00416	CcSEcCtD
Clodronate—SLC25A5—Disease—KIT—muscle cancer	0.000248	0.00241	CbGpPWpGaD
Clodronate—Mediastinal disorder—Methotrexate—muscle cancer	0.000247	0.00406	CcSEcCtD
Clodronate—Nausea—Vincristine—muscle cancer	0.000239	0.00392	CcSEcCtD
Clodronate—Pharyngitis—Doxorubicin—muscle cancer	0.000236	0.00387	CcSEcCtD
Clodronate—Urinary tract disorder—Doxorubicin—muscle cancer	0.000235	0.00385	CcSEcCtD
Clodronate—Connective tissue disorder—Doxorubicin—muscle cancer	0.000234	0.00384	CcSEcCtD
Clodronate—Urethral disorder—Doxorubicin—muscle cancer	0.000233	0.00383	CcSEcCtD
Clodronate—Pruritus—Etoposide—muscle cancer	0.00023	0.00378	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—CDKN2A—muscle cancer	0.000226	0.0022	CbGpPWpGaD
Clodronate—Diarrhoea—Etoposide—muscle cancer	0.000223	0.00366	CcSEcCtD
Clodronate—Anaemia—Methotrexate—muscle cancer	0.000221	0.00363	CcSEcCtD
Clodronate—Mediastinal disorder—Doxorubicin—muscle cancer	0.000214	0.00352	CcSEcCtD
Clodronate—SLC25A4—Disease—FOXO1—muscle cancer	0.000213	0.00207	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KIT—muscle cancer	0.000208	0.00202	CbGpPWpGaD
Clodronate—Vomiting—Etoposide—muscle cancer	0.000207	0.0034	CcSEcCtD
Clodronate—Rash—Etoposide—muscle cancer	0.000205	0.00337	CcSEcCtD
Clodronate—Dermatitis—Etoposide—muscle cancer	0.000205	0.00337	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000202	0.00332	CcSEcCtD
Clodronate—SLC25A5—Disease—MDM2—muscle cancer	0.000195	0.0019	CbGpPWpGaD
Clodronate—Infection—Methotrexate—muscle cancer	0.000194	0.00318	CcSEcCtD
Clodronate—Nausea—Etoposide—muscle cancer	0.000193	0.00318	CcSEcCtD
Clodronate—Anaemia—Doxorubicin—muscle cancer	0.000191	0.00314	CcSEcCtD
Clodronate—Skin disorder—Methotrexate—muscle cancer	0.000189	0.00311	CcSEcCtD
Clodronate—SLC25A5—Disease—PTGS2—muscle cancer	0.000188	0.00183	CbGpPWpGaD
Clodronate—Anorexia—Methotrexate—muscle cancer	0.000186	0.00305	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000175	0.00287	CcSEcCtD
Clodronate—Dyspnoea—Methotrexate—muscle cancer	0.000174	0.00285	CcSEcCtD
Clodronate—Dyspepsia—Methotrexate—muscle cancer	0.000172	0.00282	CcSEcCtD
Clodronate—Decreased appetite—Methotrexate—muscle cancer	0.000169	0.00278	CcSEcCtD
Clodronate—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000168	0.00276	CcSEcCtD
Clodronate—Infection—Doxorubicin—muscle cancer	0.000168	0.00275	CcSEcCtD
Clodronate—Skin disorder—Doxorubicin—muscle cancer	0.000164	0.00269	CcSEcCtD
Clodronate—SLC25A6—Disease—MDM2—muscle cancer	0.000164	0.00159	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KIT—muscle cancer	0.000162	0.00158	CbGpPWpGaD
Clodronate—Anorexia—Doxorubicin—muscle cancer	0.000161	0.00264	CcSEcCtD
Clodronate—SLC25A6—Disease—PTGS2—muscle cancer	0.000158	0.00153	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTGS2—muscle cancer	0.000158	0.00153	CbGpPWpGaD
Clodronate—Urticaria—Methotrexate—muscle cancer	0.000155	0.00254	CcSEcCtD
Clodronate—Abdominal pain—Methotrexate—muscle cancer	0.000154	0.00253	CcSEcCtD
Clodronate—Dyspnoea—Doxorubicin—muscle cancer	0.000151	0.00247	CcSEcCtD
Clodronate—Dyspepsia—Doxorubicin—muscle cancer	0.000149	0.00244	CcSEcCtD
Clodronate—Decreased appetite—Doxorubicin—muscle cancer	0.000147	0.00241	CcSEcCtD
Clodronate—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000146	0.00239	CcSEcCtD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000144	0.0014	CbGpPWpGaD
Clodronate—Pruritus—Methotrexate—muscle cancer	0.000138	0.00227	CcSEcCtD
Clodronate—Urticaria—Doxorubicin—muscle cancer	0.000134	0.0022	CcSEcCtD
Clodronate—Abdominal pain—Doxorubicin—muscle cancer	0.000133	0.00219	CcSEcCtD
Clodronate—Diarrhoea—Methotrexate—muscle cancer	0.000133	0.00219	CcSEcCtD
Clodronate—SLC25A6—Metabolism—PTGS2—muscle cancer	0.000132	0.00128	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MDM2—muscle cancer	0.000128	0.00124	CbGpPWpGaD
Clodronate—Vomiting—Methotrexate—muscle cancer	0.000124	0.00204	CcSEcCtD
Clodronate—SLC25A4—Disease—PTGS2—muscle cancer	0.000123	0.0012	CbGpPWpGaD
Clodronate—Rash—Methotrexate—muscle cancer	0.000123	0.00202	CcSEcCtD
Clodronate—Dermatitis—Methotrexate—muscle cancer	0.000123	0.00202	CcSEcCtD
Clodronate—Pruritus—Doxorubicin—muscle cancer	0.000119	0.00196	CcSEcCtD
Clodronate—Nausea—Methotrexate—muscle cancer	0.000116	0.0019	CcSEcCtD
Clodronate—Diarrhoea—Doxorubicin—muscle cancer	0.000116	0.0019	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000114	0.0011	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—FH—muscle cancer	0.000114	0.0011	CbGpPWpGaD
Clodronate—Vomiting—Doxorubicin—muscle cancer	0.000107	0.00176	CcSEcCtD
Clodronate—Rash—Doxorubicin—muscle cancer	0.000106	0.00175	CcSEcCtD
Clodronate—Dermatitis—Doxorubicin—muscle cancer	0.000106	0.00175	CcSEcCtD
Clodronate—SLC25A4—Metabolism—PTGS2—muscle cancer	0.000103	0.001	CbGpPWpGaD
Clodronate—Nausea—Doxorubicin—muscle cancer	0.0001	0.00165	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—TP53—muscle cancer	9.6e-05	0.000932	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	8.65e-05	0.000839	CbGpPWpGaD
Clodronate—PTGS2—Disease—ENO2—muscle cancer	7e-05	0.000679	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	6.53e-05	0.000634	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—MED12—muscle cancer	6.43e-05	0.000624	CbGpPWpGaD
Clodronate—PTGS2—Disease—HMGA1—muscle cancer	6.36e-05	0.000617	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ENO2—muscle cancer	5.86e-05	0.000569	CbGpPWpGaD
Clodronate—PTGS2—Disease—FOXO4—muscle cancer	5.7e-05	0.000553	CbGpPWpGaD
Clodronate—PTGS2—Disease—FOXO1—muscle cancer	4.21e-05	0.000409	CbGpPWpGaD
Clodronate—PTGS2—Disease—KIT—muscle cancer	3.21e-05	0.000311	CbGpPWpGaD
Clodronate—PTGS2—Disease—MDM2—muscle cancer	2.53e-05	0.000245	CbGpPWpGaD
